Contracts › 75N93023C00002
75N93023C00002: To Carry Out Development for a Drug Candidate Small Molecule Inhibitor Against Chikungunya Virus, an Alphavirus That Causes Debilitating and Sometimes Life-Threatening Disease in Humans.
Awarded to Oregon Health & Science University by National Institutes of Health (NIH).
$7.4Mobligated
$13.8Mpotential value
31 May 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023C00002 |
|---|---|
| Awardee | Oregon Health & Science University |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | OR |
| Offers received | 10 |
| Period of performance | 01 November 2022 to 31 May 2027 |
| Potential end | 31 May 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record